Medical Doctor Program year 2022 Reported 2019–2022 Source: CMS Open Payments, 2026 publication

Bruce Records

General Practice Greenwood, IN Medical Doctor

NPI 1740252667 CMS profile 782923

890 Loews Blvd, Greenwood, IN 46142

Open in the dashboard

General payments

$1,397

122 records reported · program years 2019–2022

Research payments

$0

Paid to them · None reported · program years 2019–2022

Ownership & investment interest

$0

None reported

Through program year 2022, Bruce Records of Greenwood, IN is reported in the CMS Open Payments database as having received $1,397 across 122 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2022 General $15 1
2020 General $211 14
2019 General $1,171 107

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bruce Records
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Bruce Records were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Bruce Records General Practice median Middle half National median
2019 $1,171 $107 $37–$285 $163
2020 $211 $75 $25–$213 $114
2021 $0 $93 $30–$272 $132
2022 $15 $103 $36–$279 $149
2023 $0 $106 $34–$276 $160
2024 $0 $114 $39–$290 $164
2025 $0 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2022
  1. Allergan Inc. $250 28 payments
  2. Novo Nordisk Inc $159 17 payments
  3. GlaxoSmithKline, LLC. $138 12 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $105 11 payments
  5. Lilly USA, LLC $84 6 payments
  6. AbbVie, Inc. $79 6 payments
  7. Novartis Pharmaceuticals Corporation $76 5 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $64 4 payments
  9. Sunovion Pharmaceuticals Inc. $61 4 payments
  10. Amarin Pharma Inc. $55 4 payments
  11. Other $327 25 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2022
  1. Food and Beverage $1,391 120 payments
  2. Education $6 2 payments
Products named General payments · program years 2019–2022
  1. VRAYLAR $175 18 payments
  2. TRELEGY ELLIPTA $80 7 payments
  3. ENTRESTO $76 5 payments
  4. Ozempic $74 10 payments
  5. TRULICITY $71 5 payments
  6. JARDIANCE $71 5 payments
  7. Synthroid $64 5 payments
  8. LATUDA $61 4 payments
  9. Tresiba $59 5 payments
  10. Xultophy 100/3.6 $59 5 payments
  11. Other $1,013 87 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 132 drugs

Part D claims

9,026

Median for Family Practice: 1,826

Drug cost

$751,894

Median for Family Practice: $120,094

Branded share of claims

18.9%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 92 $106,288
Trulicity Dulaglutide Brand 57 $105,133
Eliquis Apixaban Brand 69 $95,963
Ozempic Semaglutide Brand 75 $93,794
Jardiance Empagliflozin Brand 43 $62,669
Oxycontin Oxycodone Hcl Brand 23 $35,433
Januvia Sitagliptin Phosphate Brand 17 $25,049
Xarelto Rivaroxaban Brand 19 $19,331
Farxiga Dapagliflozin Propanediol Brand 14 $18,971
Rybelsus Semaglutide Brand 11 $18,258

The 10 drugs with the highest cost, of 132 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$66,130

Of which drugs: $3,649

Medicare patients

293

Average age 75

Services billed

2,375

163 women, 130 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 38%
Arthritis 36%
Ischemic heart disease 20%
Chronic kidney disease 13%
Atrial fibrillation 11%
Cancer 11%
Heart failure 10%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 32 33 $2,123
Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 Office 14 14 $1,440

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

122 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2022

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record